# Pharmacokinetics, Pharmacodynamics, and Safety of Moss-aGalactosidase A in Patients With Fabry Disease

> **NCT02995993** · PHASE1 · COMPLETED · sponsor: **Greenovation Biotech GmbH** · enrollment: 6 (actual)

## Conditions studied

- Fabry Disease

## Interventions

- **DRUG:** Moss-aGal (recombinant human alpha-galactosidase A produced in moss)

## Key facts

- **NCT ID:** NCT02995993
- **Lead sponsor:** Greenovation Biotech GmbH
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-11
- **Primary completion:** 2017-10-09
- **Final completion:** 2017-10-09
- **Target enrollment:** 6 (ACTUAL)
- **Last updated:** 2017-12-13

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02995993

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02995993, "Pharmacokinetics, Pharmacodynamics, and Safety of Moss-aGalactosidase A in Patients With Fabry Disease". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT02995993. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*